Company & Sponsor Intelligence
Acorda Therapeutics
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed4
Countries1
Therapeutic footprint
parkinsonsspinal_cord_injury
Indexed studies
NCT03887884Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT02240030Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT01777555Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT00041717Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
spinal_cord_injury · United StatesPHASE3
spinal_cord_injury · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →